ESCMID

Preliminary Programme

ESCMID/ASM Conference

Meet the Challenge of Antimicrobial Resistance

Porto, Portugal
17 – 20 September 2024



ESCMID/ASM Conference

Meet the Challenge of Antimicrobial Resistance

Porto, Portugal

Day 1 Tuesday, 17 September 2024

13:00–13 :30	**OPENING & WELCOME**

Bootcamp – Unpacking antimicrobial development

13:30–13:45	**Introduction by the chairs**
13:45–14:10	**Addressing the loss of talent from antimicrobial drug development** Jennifer Leeds (US)
14:10–15:00	**How do we get new drugs to the clinic** Claudia Zampaloni (CH) / Tomas Doyle (UK)
15:00–15:30	**Break**
15:30–16:10	**Clinical development from IND to NDA/MAA** Judith Steenbergen (US)
16:10–17:30	**Regulatory perspectives on antimicrobial development for AMR** Radu Botgros (NL) / Peter Kim (US)
17:30–18:00	**Final Roundtable**
18 :00-21 :00	**Networking Reception**

Day 2 Wednesday, 18 September 2024

Keynote - New WHO global priority pathogens list to guide R&D and public health actions including global surveillance

08:30–09:00	Hatim Sati (CH)

Symposium – How AMR surveillance guides identification of priority pathogens and informs drug development

09:00–09:20	**The CAESAR program** Biljana Kakaraskoska Boceska (BE)
09:20–09:40	**Leveraging the US CDC's National Healthcare Safety Network (NHSN) HAI tracking system to inform AMR R&D** Arjun Srinivasan (US)
09:40–10:00	**The Vivli AMR Data Register and Open Data Challenge: enabling access and research use of AMR surveillance data** Patricia Bradford (US)
10 :00–10 :20	***Neisseria gonorrhoeae*: from resistance surveillance to zoliflodacin approval** Seamus O'Brien (UK)
10:20–11:00	**Final roundtable**
11:00–11:30	**Break**

11:30–12:30	**Rapid fire talks (from selected abstracts)**
12:30–13:30	**Lunch Break**

Symposium – New Antibiotics: new vs. validated Targets: is one better?

13:30–13:50	**Novel vs. validated targets - the same finishing line** Olga Lomovskaya (US)
13:50–14:10	**New target/new chemistry: zosurabalpin** William Stubbings (CH)
14:10–14:30	**Development of inhibitors of *Pseudomonas aeruginosa* LasB as novel antivirulence agents** Anna Hirsch (DE)
14:30–14:50	**Old target/new chemistry: sulbactam-durlobactam for CRAB** John O'Donnell (US)
14:50–15:10	**Old target/optimised chemistry: BV100 for CRAB** Glenn Dale (US)
15:10–15:30	**Final discussion**
15:30–16:00	**Break**

Young Investigators presentations

16:00–16:30	**Use of system-wide simulation approaches for AMR** Alessandro Gerada (UK)
16:30–17:00	**New advancements in preclinical PK-PD models** Katharina Rox (DE)
17:00–18:30	**Poster Presentations with Light Reception**

Day 3 Thursday, 19 September 2024

Symposium – Antimicrobial stewardship: getting to the right new agent to the right patient at the right time

08:30–09:00	**What is the current state of using new agents, and what are the barriers to using them?** TBA
09:00–09:30	**What is the clinical impact of not using new agents when appropriate?** Sameer Kadri (US)
09:30–10:00	**How can diagnostic and clinical approaches promote appropriate access to novel agents?** Valérie Raymond-Schwartzmann (FR)
10:00–10:30	**Final roundtable**
10:30–11:00	**Break**
11:00–12:00	**Rapid fire talks (from selected abstracts)**
12:00–13:30	**Lunch**

ESCMID/ASM Conference
Meet the Challenge of Antimicrobial Resistance
Porto, Portugal

ESCMID

Symposium – Are we ready to use artificial intelligence in our fight against antimicrobial resistance?

13:30–13:50	**AI and routine real life microbiology data to address antimicrobial resistance** Adrian Egli (CH)
13:50–14:10	**Repurposing drugs as antimicrobial agents using AI** Jonathan Stokes (CA)
14:10–14:30	**AI concepts and application in antimicrobial drug discovery** Cesar de la Fuente (US)
14:30–14:50	**AI and clinical decisions in infected patients with MDR microorganisms** TBA
14:50–15:30	**Final discussion**
15:30–16:00	**Break**

Young Investigators presentations

16:00–16:30	**Immune approaches for Infectious diseases** Jessica Field (US)
16:30–17:00	**Discovery and optimization of novel bacterial sliding clamp (DnaN) inhibitors with potent antibiotic activities** Walid Elgaher (DE)
17:00–18:30	**Poster Presentations with Light Reception**

Day 4 Friday, 20 September 2024

Symposium – Do preclinical models really translate to clinical efficacy?

08:30–08:45	**In vivo models of efficacy – values and caveats** Jennifer Hoover (US)
08:45–09:00	**Role of in vitro models and the importance of understanding resistance** Alasdair Macgowan (UK)
09:00–09:15	**Challenges during regulatory submission** Sujata Bhavnani (US)
09:15–09:30	**Regulatory expectations of preclinical models** Sumathi Nambiar (US)
09:30–09:45	**Gaps in translation from clinicians perspective** Joseph Kuti (US)
09:45–10:30	**Final discussion**
10:30–11:00	**Break**
11:00–12:00	**Session TBA**
12:00–12:30	**Closing Remarks**
12:30–13:30	**Farewell Cocktail**